PATENT CLAIM ANALYSIS

Application Number: 16226175
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-07
Patent Classification: ["424", "153100"]

Abstract:
The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.

Claim (Index 25):
The method of  claim 24 , wherein the at least one additional active agent is selected from the group consisting of a protein kinase inhibitor, a PD-1/PDL-1 pathway inhibitor, a checkpoint inhibitor, a platinum based anti-neoplastic agent, a topoisomerase inhibitor, a nucleoside metabolic inhibitor, an alkylating agent, an intercalating agent, a tubulin binding agent, and combinations thereof.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 98.0
- Lexical Diversity: 1.125
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15524844', '15113154', '15213829', '15645544', '14771817']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7813334090097054
- 35 USC 102 Novelty (BERT): 0.6101819361538475
- Combined Prediction Score: 0.7642182617241196
- Mean Citation Score: 346.191074
- Max Citation Score: 630.56506
- Similarity Product: 468.6197562124586

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test